|Assembly Biosciences Inc -- USA Stock|| |
USD 59.67 2.69 4.31%
Non-Executive Chairman of the Board
Mr. William Ringo is Independent NonExecutive Chairman of the Board of Company, Since July 2010, Mr. Ringo was a senior advisor with Barclays Capital, the global investment banking division of Barclays Bank PLC. Since July 2010, Mr. Ringo has also served as a strategic advisor with Sofinnova Ventures, a life sciencesfocused investment firm. Prior to his advisory roles with Barclays Capital and Sofinnova Ventures, Mr. Ringo served as senior Vice President of Strategy and Business Development for Pfizer Inc., a biopharmaceutical company, from April 2008 until his retirement in April 2010. From 2004 to 2006, Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a private biotechnology company acquired by Amgen. Mr. Ringo served on the Onyx Pharmaceuticals, Inc. board of directors from Feburary 2011 until the October 2013 acquisition by Amgen
Age: 69 Chairman Since 2015 MBA
Ringo received his B.S. in business administration and his M.B.A. from the University of Dayton.
William Ringo Latest Insider Activity
The company has return on total asset (ROA)
of (24.41) %
which means that it has lost $24.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (44.36) %
meaning that it created substantial loss on money invested by shareholders.
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Drug Manufacturers - Major classification in USA and traded on Nasdaq Capital Markets exchange. It employs 79 people.Assembly Biosciences Inc (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 79 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.